Andere talen Enzymatica AB

Aandelen

Vertraagde tijd Nasdaq Stockholm Andere beurzen 09:00:03 16-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,2 ^SEK	0,00%		+1,91%	-18,88%

25/04	Enzymatica AB (publ) rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI
27/03	Enzymatica AB (publ) kondigt samenstelling benoemingscommissie aan	CI

Bulletin from annual general meeting of Enzymatica AB (publ) on May 7, 2024	07/05
BioStock: MDR certification was Enzymatica's highlight in Q1	29/04
Enzymatica Q1 - Continued growth in own markets, but a lack of partner orders	26/04
Interim report Q1/2024: MDR certification opens up great commercial opportunities	25/04
Enzymatica AB Reports Earnings Results for the First Quarter Ended March 31, 2024	25/04
Enzymatica publishes annual report for 2023	09/04
Notice of Annual General Meeting 2024 in Enzymatica AB (publ)	27/03
Enzymatica AB Announces Composition of Nomination Committee	27/03
BioStock: Enzymatica comments on MDR certification for ColdZyme	20/03
Enzymatica announces outcome of new rights issue	14/03
Enzymatica Obtains CE Marking for ColdZyme Mouth Spray	11/03
ColdZyme® certified under the new EU medical device regulation (MDR)	11/03
BioStock: Enzymatica's partners await MDR certification and study results	26/02
Enzymatica publishes information memorandum about rights issue of shares	19/02
Enzymatica Q4 - Important year ahead and an expected rights issue	19/02
Enzymatica's rights issue is secured to 100 percent	16/02
Year-end report 2023: Scientific and regulatory progress generating international interest	16/02
Enzymatica AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	16/02
Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4 million	16/02
Enzymatica's Chairman to BioStock: "Our new research data makes 2024 an exciting year"	21/12

Geen resultaten voor deze zoekopdracht